News Image

Zimmer Biomet Holdings Inc (NYSE:ZBH) - A Reliable Dividend Stock Worth Considering

By Mill Chart

Last update: Jun 12, 2025

Zimmer Biomet Holdings Inc (NYSE:ZBH) stands out as a strong candidate for dividend investors, according to our Best Dividend Stocks screener. The company combines a solid dividend track record with decent profitability and financial health, making it an appealing option for income-focused portfolios.

Zimmer Biomet stock chart

Dividend Strength

  • Consistent Payouts: ZBH has paid dividends for at least 10 years without reductions, demonstrating reliability.
  • Sustainable Payout Ratio: The company pays out just 21.28% of its income as dividends, well below levels that could threaten sustainability.
  • Modest but Stable Growth: While the annual dividend growth rate is modest at 0.19%, earnings growth supports future increases.

Profitability & Valuation

  • Strong Margins: ZBH boasts an Operating Margin of 19.59%, outperforming 92.55% of industry peers.
  • Reasonable Valuation: With a P/E ratio of 11.97, the stock trades at a discount compared to both the industry and the S&P 500.

Financial Health

  • Manageable Debt: A Debt-to-Equity ratio of 0.53 indicates moderate leverage, though liquidity metrics are in line with industry averages.
  • Positive Cash Flow: The company generates consistent operating cash flow, reinforcing dividend sustainability.

For a deeper dive into ZBH’s fundamentals, review the full analysis report.

Our Best Dividend Stocks screener provides more high-quality dividend stock ideas, updated daily.

Disclaimer

This is not investment advice. Always conduct your own research before making investment decisions.

ZIMMER BIOMET HOLDINGS INC

NYSE:ZBH (7/3/2025, 8:19:13 PM)

After market: 93.64 -0.03 (-0.03%)

93.67

+0.17 (+0.18%)



Find more stocks in the Stock Screener

ZBH Latest News and Analysis

ChartMill News Image11 days ago - ChartmillZIMMER BIOMET HOLDINGS INC (NYSE:ZBH) - An Undervalued Stock Worth Considering

ZIMMER BIOMET (NYSE:ZBH) is an undervalued medical device stock with strong profitability, a reasonable dividend, and improving growth prospects. A solid pick for value investors.

Follow ChartMill for more